TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15364158

Group type: EXPERIMENTAL
Intervention: Preprandial dosing of BIAsp 30 (b.i.d. injections before meals)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Postprandial dosing of BIAsp 30 (b.i.d. injections after meals)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Postprandial dosing of BIAsp 30
Number of subjects: 93

Group type: COMPARATOR
Intervention: Preprandial dosing of BIAsp 30
Number of subjects: 93

Group type: COMPARATOR
Intervention: Postprandial injection
Number of subjects: 93
Study: 11454372

Group type: COMPARATOR
Intervention: Traditional epidural (n=353)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose combined spinal epidural (n=351)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose infusion epidural (n=350)
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose techniques
Number of subjects: 1054

Group type: EXPERIMENTAL
Intervention: Low-dose infusion group
Number of subjects: 1054
Study: 9498439

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60-mg retinol equivalent, 200,000 IU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 7989683

Group type: EXPERIMENTAL
Intervention: Infiltration anesthesia administered into the incised edges of the wound
Number of subjects: 81

Group type: COMPARATOR
Intervention: Infiltration anesthesia administered into the skin surrounding the wound
Number of subjects: 81
Study: 2563896

Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography followed by prophylactic PTCA)
Number of subjects: 3262

Group type: COMPARATOR
Intervention: Conservative strategy (PTCA only if ischemia occurred)
Number of subjects: 3262

Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (15 mg immediately, followed by oral metoprolol)
Number of subjects: 3262

Group type: COMPARATOR
Intervention: Deferred oral beta-blockade (started on day 6)
Number of subjects: 3262
Study: 31429625

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30650202

Group type: EXPERIMENTAL
Intervention: Adaptive randomization ratio change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sample size reestimation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical adjustment for final analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonproportional increase in sample size
Number of subjects: 0
Study: 29078199

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) encompassing three individual sessions and regular home practice
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control condition combining psycho-educational components and regular rest periods
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 74
Study: 25556976

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) 400 mg
Number of subjects: 502

Group type: COMPARATOR
Intervention: Oral aripiprazole (6-24 mg/day)
Number of subjects: 502
Study: 23995469

Group type: EXPERIMENTAL
Intervention: CHOICES intervention (Web-based, multimedia educational intervention)
Number of subjects: 234

Group type: COMPARATOR
Intervention: e-Book (attention-control usual care intervention)
Number of subjects: 234
Study: 21756809

Group type: EXPERIMENTAL
Intervention: TAC (docetaxel + pirarubicin + cyclophosphamide)
Number of subjects: 139

Group type: COMPARATOR
Intervention: TEC (docetaxel + epirubicin + cyclophosphamide)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide + pirarubicin + fluorouracil)
Number of subjects: 139

Group type: COMPARATOR
Intervention: CEF (cyclophosphamide + epirubicin + fluorouracil)
Number of subjects: 139
Study: 19500396

Group type: EXPERIMENTAL
Intervention: CT drainage for group A (pseudocysts > 1l)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group B (pseudocysts < 1l)
Number of subjects: 27
Study: 17117016

Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day
Number of subjects: 60
Study: 14665607

Group type: EXPERIMENTAL
Intervention: MVAC
Number of subjects: 220

Group type: COMPARATOR
Intervention: DC
Number of subjects: 220
Study: 11069512

Group type: EXPERIMENTAL
Intervention: Surface microscopy education intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study: 9272926

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) via Turbuhaler (TH)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) via pressurized metered-dose inhaler (pMDI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 8392270

Group type: EXPERIMENTAL
Intervention: 50% bladder filling
Number of subjects: 71

Group type: COMPARATOR
Intervention: 75% bladder filling
Number of subjects: 71
Study: 2942747

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30646030

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction diet (500-600 kcal/d for 2 nonconsecutive days per week)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous energy restriction diet (1200-1500 kcal/d for 7 days per week)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction diet
Number of subjects: 137

Group type: COMPARATOR
Intervention: Continuous energy restriction diet
Number of subjects: 137
Study: 27716211

Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) with personalised risk information
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) plus risk group (Caucasian participants, n = 66)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Gene score (GS) in UK healthy men (n = 1360)
Number of subjects: 211
Study: 24335055

Group type: EXPERIMENTAL
Intervention: 800 IU (20 μg) vitamin D₃
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 2000 IU (50 μg) vitamin D₃
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 4000 IU (100 μg) vitamin D₃
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 23099311

Group type: EXPERIMENTAL
Intervention: Implicit dosage interval (6 ML by mouth every 12 hours)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Explicit dosage interval (6 ML by mouth at 7 AM and 7 PM)
Number of subjects: 193
Study: 20145273

Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/day for 6 months followed by 400 mg/day as maintenance therapy)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard-dose imatinib (400 mg/day)
Number of subjects: 227
Study: 18330677

Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 352

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study: 15793191

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study: 12220050

Group type: EXPERIMENTAL
Intervention: Provision of cognitively stimulating activities (HOME scales)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Maternal emotional distress
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Parenting practices (authoritative and authoritarian behavior)
Number of subjects: 493
Study: 10664054

Group type: EXPERIMENTAL
Intervention: dimenhydrinate suppositories
Number of subjects: 99

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: bimedial Faden operation (BMF)
Number of subjects: 99

Group type: COMPARATOR
Intervention: horizontal recess-resect procedure (R&R)
Number of subjects: 99
Study: 8878243

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg once daily for 4 days)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (approximately 40 mg/kg/day in 3 divided doses for 10 days)
Number of subjects: 263
Study: 1985163

Group type: EXPERIMENTAL
Intervention: Simultaneous continuous infusions of MTX and VM‐26
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Sequential continuous infusions of MTX and VM‐26
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study: 6315120

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 308

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Metronidazole and Cefotaxime
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Cefotaxime or Metronidazole and Cefotaxime
Number of subjects: 308
Study: 31234639

Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondihydropyridine CCBs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydropyridine CCBs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors and β-blockers
Number of subjects: 0
Study: 28691885

Group type: EXPERIMENTAL
Intervention: Fitusiran (0.225, 0.45, 0.9, or 1.8 mg/kg or fixed dose of 80 mg, once monthly)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fitusiran (0.03 mg/kg, single subcutaneous injection)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fitusiran (0.015, 0.045, or 0.075 mg/kg, once weekly)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Fitusiran (once monthly)
Number of subjects: 29
Study: 25135064

Group type: EXPERIMENTAL
Intervention: Highly interactive HIV and STI education program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Non-interactive, lecture-based program
Number of subjects: 101
Study: 23364237

Group type: EXPERIMENTAL
Intervention: Sarpogrelate (100 mg, tid)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Aspirin (100 mg, qd)
Number of subjects: 176
Study: 21283148

Group type: EXPERIMENTAL
Intervention: Device closure of PFO
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study: 19593174

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 12112177

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg OD)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10025743

Group type: EXPERIMENTAL
Intervention: Atopy Patch Test (APT) with 3000 to 10,000 PNU/g of Dermatophagoides pteronyssinus, cat dander, grass, birch, and mugwort pollen allergen extracts in petrolatum
Number of subjects: 253

Group type: COMPARATOR
Intervention: Skin prick test
Number of subjects: 253

Group type: COMPARATOR
Intervention: Radioallergosorbent test (RAST)
Number of subjects: 253
Study: 8703659

Group type: EXPERIMENTAL
Intervention: Inhaled magnesium sulphate (0, 90, 135, 180, 360 mg)
Number of subjects: 39
Study: 2180331

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg daily)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study: 101316

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (800 mg/day for 1 week or a single dose of 1.0 g by mouth)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (by inhalation)
Number of subjects: 20
Study: 7058674

Group type: EXPERIMENTAL
Intervention: Arginine aspartate (250 mg/dg/day for one week)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 30312812

Group type: EXPERIMENTAL
Intervention: Preoperative Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard postoperative care (Control)
Number of subjects: 48
Study: 29217376

Group type: EXPERIMENTAL
Intervention: VRC5288 (Zika virus and Japanese encephalitis virus chimera)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: VRC5283 (wild-type Zika virus)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: VRC5283 (wild-type Zika virus) via split-dose needle-free injection
Number of subjects: 125
Study: 26965174

Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Intervention (ICBI); n=88
Number of subjects: 177

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU); n=89
Number of subjects: 177
Study: 25253174

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/bid)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 22731240

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ondansetron in combination with dexamethasone
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study: 20831698

Group type: EXPERIMENTAL
Intervention: Eltrombopag 75 mg q.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo q.i.d.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg b.i.d.
Number of subjects: 36
Study: 18159905

Group type: EXPERIMENTAL
Intervention: Potent topical steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel immunomodulatory therapeutic approaches
Number of subjects: 0
Study: 16129209

Group type: EXPERIMENTAL
Intervention: Low-calcium session (L-HF) with calcium ion concentration of 2.5 mEq/L (1.25 mmol/L)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High-calcium session (H-HF) with calcium ion concentration of 3.5 mEq/L (1.75 mmol/L)
Number of subjects: 12
Study: 11815895

Group type: EXPERIMENTAL
Intervention: Oral antioxidant micronutrient mixture (beta-carotene 18 mg/day, vitamin C 750 mg/day, vitamin E 600 mg/day)
Number of subjects: 297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 297
Study: 10070054

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 4 mmol/l
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Blood glucose concentration at 9 mmol/l
Number of subjects: 10
Study: 7734364

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (r‐HuEPO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study: 1849133

Group type: EXPERIMENTAL
Intervention: OKY-046 (thromboxane A2 synthetase inhibitor)
Number of subjects: 11
Study: 6997220

Group type: EXPERIMENTAL
Intervention: Meditation group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study: 31416357

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation plus platelet inhibition (OAC+PI)
Number of subjects: 4042

Group type: COMPARATOR
Intervention: Platelet inhibition only
Number of subjects: 4042
Study: 30348124

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 28.0 kg/m2)
Number of subjects: 32482

Group type: EXPERIMENTAL
Intervention: Overweight (24.0 ≤ BMI < 28.0 kg/m2)
Number of subjects: 32482

Group type: COMPARATOR
Intervention: Normal weight (18.5 ≤ BMI < 24.0 kg/m2)
Number of subjects: 32482
Study: 26917112

Group type: EXPERIMENTAL
Intervention: DRV/r 800/100 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: ATV/r 300/100 mg once daily
Number of subjects: 27
Study: 23845099

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention (six-month duration)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 240
Study: 21842159

Group type: EXPERIMENTAL
Intervention: Ayahuasca (0.75 mg DMT/kg bodyweight)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 9
Study: 19398067

Group type: EXPERIMENTAL
Intervention: 3g of oral Myelophil per day
Number of subjects: 36
Study: 17124249

Group type: EXPERIMENTAL
Intervention: Shared care with annual hospital review (SCSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aggressive treatment delivered in hospital (ATH)
Number of subjects: 100
Study: 16239811

Group type: EXPERIMENTAL
Intervention: Disruption of the infrapatellar fat pad contour on lateral radiographs
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Routine lateral view radiographs
Number of subjects: 14
Study: 12037070

Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dual-nucleoside treatment arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm (plasma HIV-1 RNA <500 copies/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indinavir treatment arm (plasma HIV-1 RNA >or=500 copies/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Samples with plasma RNA levels <50 copies/ml
Number of subjects: 0
Study: 12016904

Group type: EXPERIMENTAL
Intervention: roxithromycin dispersible tablet (formulation A)
Number of subjects: 10

Group type: COMPARATOR
Intervention: conventional tablet (formulation B)
Number of subjects: 10
Study: 8551026

Group type: COMPARATOR
Intervention: Nursing reorganization including intensified handwashing, single-use equipment, and waste control.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nursing procedures before reorganization (control group).
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Nursing reorganization procedures post-implementation.
Number of subjects: 64
Study: 2173646

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 199

Group type: COMPARATOR
Intervention: Sodium bicarbonate (prior 2-year period)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: No drug therapy between shocks
Number of subjects: 199
Study: 210476

Group type: EXPERIMENTAL
Intervention: 25 mg chlorpromazine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 75 mg chlorpromazine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31240721

Group type: EXPERIMENTAL
Intervention: Pulmonary vessel segmentation and removal using two cascaded CNNs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vessel removal method
Number of subjects: 50
Study: 27518129

Group type: EXPERIMENTAL
Intervention: Picosecond laser (PSL)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nanosecond laser (NSL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both PSL and NSL
Number of subjects: 21
Study: 24875927

Group type: EXPERIMENTAL
Intervention: HDTBR with countermeasures (centrifugation or aerobic exercise)
Number of subjects: 22

Group type: COMPARATOR
Intervention: HDTBR without countermeasures
Number of subjects: 22
Study: 24020660

Group type: EXPERIMENTAL
Intervention: Invasive cooling (Coolgard®)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-invasive cooling (Arctic Sun®)
Number of subjects: 80
Study: 21516308

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 1691
Study: 18653496

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg kg(‐1)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (C)
Number of subjects: 54
Study: 16525746

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate (Fleet)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Picoprep (sodium picosulfate-based preparation)
Number of subjects: 225
Study: 12525827

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered as a 90- to 110-μg/kg bolus dose every second hour.
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered for major surgery and life-threatening bleeding.
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) with longer intervals between doses after the first 24 hours.
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven®) at higher doses in in vitro experiments.
Number of subjects: 6500
Study: 10770171

Group type: EXPERIMENTAL
Intervention: Physiological study (hydrocortisone infusion for 48 h in a pulsatile and diurnal pattern)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Constant study (same total dose of hydrocortisone as physiological study, but with pulses of equal magnitude spaced evenly)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Reversed study (same total dose of hydrocortisone, but with diurnal pattern shifted 12 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Baseline study (saline infusion for 48 h)
Number of subjects: 7
Study: 8851456

Group type: EXPERIMENTAL
Intervention: 10-mg CR oxycodone tablet every 12 hours for 4 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: 5 mL of 1-mg/1 mL IR oxycodone solution every 6 hours for 4 days
Number of subjects: 24
Study: 1471584

Group type: EXPERIMENTAL
Intervention: Home visits by district nurse after hospital discharge
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual discharge procedures (Control)
Number of subjects: 344
Study: 6726654

Group type: EXPERIMENTAL
Intervention: Imipramine with cimetidine (300 mg every 6 hr)
Number of subjects: 6
Study: 30161278

Group type: EXPERIMENTAL
Intervention: Mineralized solvent-dehydrated bone allograft (SDBA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mineralized freeze-dried bone allograft (FDBA)
Number of subjects: 44
Study: 29101022

Group type: EXPERIMENTAL
Intervention: LSD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26002590

Group type: EXPERIMENTAL
Intervention: α-tocopherol supplementation
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 25555856

Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Audiobook
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (silence)
Number of subjects: 60
Study: 23615090

Group type: EXPERIMENTAL
Intervention: Surgical intervention (extratemporal resections)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Complete resection of ictal onset areas
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Absence of acute postoperative seizures
Number of subjects: 60
Study: 22009369

Group type: EXPERIMENTAL
Intervention: Intravenous bolus of lipopolysaccharide (LPS, 4 ng/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 18295324

Group type: EXPERIMENTAL
Intervention: Swimming program
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Walking program
Number of subjects: 116

Group type: COMPARATOR
Intervention: Behavioural intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116